

09 December 2025

Futura Medical plc
("Futura", "the Group" or the "Company")

Block Listing Six Monthly Return

Futura Medical (AIM: FUM), the consumer healthcare Group behind Eroxon®, that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, makes the following update on its block listings, pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies. All figures relate to options over Ordinary Shares of 0.2 pence each (Ordinary Shares).

Name of <i>applicant</i> :		Futura Medical Plc	
Name of scheme(s):		Unapproved Share Option Scheme Unapproved Share Incentive Scheme EMI Share Option Scheme LTIP Scheme	
Period of return:	From:	1 June 2025	To: 8 December 2025
Balance of unallotted securities under scheme(s) from previous return:		18,528,545	
<u>Plus:</u> The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		USOS: nil USIS: nil EMI: nil LTIP: nil	
<u>Less:</u> Number of securities issued/allotted under scheme(s) during period:		USOS: nil USIS: nil EMI: nil LTIP: 2,290,975	
<u>Equals:</u> Balance under scheme(s) not yet issued/allotted at end of period:		16,237,570	
Number and class of securities originally admitted and the date of admission		USOS Total: 3,882,912 814,424 25 May 2011 1,202,280 8 October 2013 1,466,208 25 May 2017 400,000 30 May 2018 USIS Total: 425,000 425,000 30 November 2018 EMI Total: 8,112,088 1,520,576 25 May 2011 1,467,720 8 October 2013 1,893,792 25 May 2017 790,000 30 May 2018 1,340,000 30 November 2018 1,100,000 2 February 2023 LTIP Total: 15,035,617 4,444,942 2 February 2023 10,590,675 3 November 2023	

Contacts:

Futura Medical plc	Alex Duggan	investor.relations@futura-medical.com
	Chief Executive Officer	+44 (0)1483 685 670
	Angela Hildreth	www.futura-medical.com
	Finance Director and COO	
Panmure Liberum	Emma Earl, Will Goode, Mark Rogers (Corporate Finance)	+44 (0)20 3100 2000
Nominated Adviser and Broker		
Turner Pope Investments (TPI) Ltd - Broker	Guy McDougall, Andrew Thacker	+44 (0) 20 3657 0050
Alma Strategic Communications	Rebecca Sanders-Hewett, Sam Modlin, Emma Thompson	+44 (0)20 3405 0205 futura@almastrategic.com

Notes to Editors:

Futura Medical plc (AIM: FUM) is the developer of innovative sexual health products, including lead product Eroxon[®] and development products WSD4000 and Eroxon[®] Intense. Our core strength lies in our research, development and commercialisation of topically delivered gel formulations in sexual health products.

Sexual health issues are prevalent in both men and women. Erectile Dysfunction ("ED") impacts 1 in 5 men globally across all adult age brackets, with approximately half of all men over 40 experiencing ED and 25% of all new diagnoses being in men under 40. Around 60% of women experience at least one symptom of sexual dysfunction, and only one in four women seek professional help, and remain chronically underserved.

Eroxon[®], Futura's clinically proven lead product, has been developed for the treatment of ED. The highly differentiated product, which is the only topical gel treatment for ED available over the counter and helps men get an erection in ten minutes, addresses significant unmet needs in the ED market. Eroxon[®] has been nominated for a number of healthcare industry awards and has won two to-date.

Futura has distribution partners in place in a number of major consumer markets including Haleon in the US, the largest market for ED in the world, and Cooper Consumer Health in Europe.

WSD4000 is a topical treatment designed for the symptoms of impaired sexual response and function in women. There is currently no regulatory approved OTC treatment available for impaired sexual response and function in women. WSD4000 has the potential to be an effective, breakthrough treatment for the common symptoms associated with impaired sexual response and function, such as lack of desire, arousal and lubrication.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

BLRTLBATMTAMBRA